2023-05-10 07:09:24 ET
- Alaunos Therapeutics press release ( NASDAQ: TCRT ): Q1 GAAP EPS of -$0.04 in-line.
- As of March 31, 2023, Alaunos had approximately $37.4 million in cash balances, which included restricted cash of approximately $13.9 million.
- Based on current operating plans, the Company expects its operating outflows, excluding debt service costs, for 2023 to be between approximately $35 million and $40 million.
- The Company expects to have sufficient cash resources to fund research and development programs and operations into the fourth quarter of 2023.
For further details see:
Alaunos Therapeutics GAAP EPS of -$0.04 in-line